In relapsed/refractory settings, integrating noncovalent BTK inhibitors into individualized treatment strategies—including as bridging therapies to cellular modalities like Chimeric Antigen Receptor T-cell (CAR-T)—may optimize outcomes and advance toward curative interventions in CLL. Here, BTK is linked to B-cell chronic lymphocytic leukemia.